Healthcare M&A and Valuation
News and Insights

On October 29, 2025, Thermo Fisher Scientific Inc. (NYSE: TMO)  announced a definitive agreement  to acquire Clario Holdings, Inc., a leading global provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg, Nordic Capital, Novo Holdings and Cinven for approximately $8.875 billion in cash at closing, with additional deferred and contingent payments of up to ~$525 million tied to future performance. The transaction, subject to customary re

In July 2025, Aurobindo Pharma USA Inc., the wholly owned U.S. subsidiary of Indian generics manufacturer Aurobindo Pharma Ltd., entered into a definitive agreement  to acquire Lannett Co., Inc., a U.S. based producer of complex generic pharmaceuticals, for an enterprise value of approximately $250 million on a cash‑free, debt‑free basis. The transaction, which is expected to close within 8–12 months pending regulatory approvals, will provide Aurobindo with full ownership of

Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, announced ...

The healthcare M&A industry witnessed a significant tremor today with the announcement that Novo Holdings, the investment arm of the...

Sterling Pharma Solutions, a pharmaceutical contract development and manufacturing organization (CDMO), received a significant minority...

Syneos Health, Inc. , an integrated biopharmaceutical solutions organization, announced that it has entered into a definitive agreement...